606 participants with Clostridium Difficile Associated Diarrhea (CDAD) participated in this
study and received either oral vancomycin or CB-183,315 (surotomycin) in a blinded fashion.
Treatment lasted for 10 days and participants were followed up for at least 40 days and a
maximum of 100 days. The purpose of this study was to evaluate how well surotomycin treats
CDAD as compared to vancomycin.